6,762 reports of this reaction
1.7% of all INSULIN GLARGINE reports
#11 most reported adverse reaction
FATIGUE is the #11 most commonly reported adverse reaction for INSULIN GLARGINE, manufactured by sanofi-aventis U.S. LLC. There are 6,762 FDA adverse event reports linking INSULIN GLARGINE to FATIGUE. This represents approximately 1.7% of all 399,332 adverse event reports for this drug.
Patients taking INSULIN GLARGINE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for INSULIN GLARGINE, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for INSULIN GLARGINE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 6,762 FDA reports for INSULIN GLARGINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 1.7% of all adverse event reports for INSULIN GLARGINE, making it a notable side effect.
If you experience fatigue while taking INSULIN GLARGINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.